

# Claudia Scholl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/846172/publications.pdf>

Version: 2024-02-01

22  
papers

1,813  
citations

840119

11  
h-index

839053

18  
g-index

22  
all docs

22  
docs citations

22  
times ranked

3610  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells. <i>Cell</i> , 2009, 137, 821-834.	13.5	510
2	BCAT1 restricts $\hat{\pm}$ KG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. <i>Nature</i> , 2017, 551, 384-388.	13.7	261
3	The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. <i>Nature</i> , 2020, 585, 293-297.	13.7	219
4	Small-molecule-induced polymerization triggers degradation of BCL6. <i>Nature</i> , 2020, 588, 164-168.	13.7	143
5	Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. <i>Blood</i> , 2014, 124, 13-23.	0.6	139
6	Deregulation of Signaling Pathways in Acute Myeloid Leukemia. <i>Seminars in Oncology</i> , 2008, 35, 336-345.	0.8	136
7	The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. <i>Journal of Clinical Investigation</i> , 2007, 117, 1037-1048.	3.9	127
8	Comparative analysis of KRAS codon 12, 13, 18, 61 and 117 mutations using human MCF10A isogenic cell lines. <i>Scientific Reports</i> , 2015, 5, 8535.	1.6	111
9	Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. <i>Journal of Experimental Medicine</i> , 2012, 209, 697-711.	4.2	63
10	HSP90 Supports Tumor Growth and Angiogenesis through PRKD2 Protein Stabilization. <i>Cancer Research</i> , 2014, 74, 7125-7136.	0.4	52
11	Stk33 is required for spermatid differentiation and male fertility in mice. <i>Developmental Biology</i> , 2018, 433, 84-93.	0.9	13
12	Aberrant Expression of the Homeobox Gene CDX2 in Acute Myeloid Leukemia.. <i>Blood</i> , 2006, 108, 8-8.	0.6	11
13	Requirement for LIM kinases in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 3173-3185.	3.3	8
14	Gene Expression Profiling Identifies Distinct Subclasses in Core Binding Factor Acute Myeloid Leukemia.. <i>Blood</i> , 2005, 106, 673-673.	0.6	7
15	BTB/BCL6 dimers as building blocks for reversible drug-induced protein oligomerization. <i>Cell Reports Methods</i> , 2022, 2, 100193.	1.4	5
16	Cdx4 Upregulates Hox Gene Expression and Generates Acute Myeloid Leukemia Alone and in Cooperation with Meis1a in a Murine Model.. <i>Blood</i> , 2006, 108, 10-10.	0.6	3
17	High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 886-886.	0.6	3
18	Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles.. <i>Blood</i> , 2007, 110, 206-206.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Identification of Distinct inv(16) Subclasses in Adult Acute Myeloid Leukemia Based on Gene Expression Profiling.. Blood, 2004, 104, 2037-2037.	0.6	0
20	KIT Mutations Define Characteristic Gene Expression Signatures in Core Binding Factor Leukemias.. Blood, 2007, 110, 3163-3163.	0.6	0
21	High-Throughput RNA Interference Screening Identifies Synthetic Lethality Between Oncogenic KRAS Dependency and Suppression of STK33. Blood, 2008, 112, 3806-3806.	0.6	0
22	Myeloid Leukemogenesis Driven by Aberrant CDX2 Expression Involves Transcriptional Repression of KLF4 and Deregulated PPAR $\gamma$ Signaling. Blood, 2011, 118, 1355-1355.	0.6	0